Global Search | Novartis

Hide Filters

Showing 1716 results

Press release / Jun 27, 2022

New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)

New data from the Phase 3 ASCLEPIOS I/II trials and ALITHIOS open-label extension show that after four years nearly 8 out of 10 of people with relapsing multiple sclerosis (RMS) treated continuously…
Press release / Dec 15, 2020

Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema

In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)1In a…
Press release / Sep 07, 2020

Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings

High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair…
Press release / Aug 11, 2023

Novartis completes acquisition of Chinook Therapeutics

Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin…
Press release / Jan 17, 2018

Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL

Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted…
Press release / Jul 29, 2015

Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd

Novartis is spinning off three mid stage clinical assets to Mereo for further development in exchange for equity Novartis will have a stake in the success of the development of these compounds…
Press release / May 12, 2018

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a…
Press release / Mar 28, 2018

Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO

Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,…
Press release / Dec 08, 2018

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine…
Press release / May 10, 2019

Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS

Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya® (fingolimod) 0.5mg had significantly fewer relapses than patients…